Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
DEA explains three‑step scheme and decision limits for distinguishing hemp from marijuana
Loading...
Summary
The Drug Enforcement Administration told an RTI webinar it uses a three‑part analytical scheme (micro/macroscopic exam, 4‑AP color typification, GC‑MS ratio) with a conservative 1% GCMS decision limit; inconclusive results are referred for HPLC‑UV quantitation on request.
At an RTI International Forensic Technology Center of Excellence webinar, Dr. Sandra Rodriguez Cruz of the DEA outlined the agency’s analytical approach for distinguishing hemp from marijuana and explained why some field or preliminary results are reported as “inconclusive.” The DEA’s scheme applies a microscopic/macroscopic examination, a 4‑aminophenol (4‑AP) typification color test and a GC‑MS ratio assessment; the agency requires consistent support from those three lines of evidence before reporting a sample as marijuana.
Sandra Rodriguez Cruz, senior research chemist at the DEA Special Testing and Research Laboratory, said the agency selected a 1% THC decision limit for the GC‑MS ratio to account for instrument variability and to avoid false positives near the statutory threshold: “We wanted such a result … to be supported by three different tests,” she said. The DEA validated the approach through ruggedness and interlaboratory studies and reported that roughly 95–96% of submitted exhibits that were reported as marijuana met the scheme’s combined criteria.
When a sample is inconclusive under the initial scheme, the DEA provides an option for further analysis: a full quantitative method using liquid chromatography with UV detection (HPLC‑UV). Rodriguez Cruz said that since implementing the analytical scheme the DEA received about 2,100 submissions; about 60 were initially reported as inconclusive and just five or six went on to full quantitation, which in a few cases produced higher purity readings (two exhibits showed ~10% THC; two measured about 0.33%).
The DEA’s reports for concentrates and extracts list delta‑9 tetrahydrocannabinol (THC) and include a reported quantitative purity with an uncertainty budget but do not list detailed LOQ/LOD on the public report for controlled substances. Rodriguez Cruz emphasized the different sample preparations and decision points for the initial GC‑MS scheme versus the lower‑limit quantitative method, and said DEA analysts can explain the laboratory steps to a court if needed.
The webinar Q&A also highlighted operational practices tied to the scheme: field agents use DEA‑provided sampling procedures (statistical/hypergeometric sampling for large populations), and the DEA has incorporated sampling guidance into the agents’ manual.
What happens next: samples flagged as inconclusive may undergo HPLC‑UV quantitation on request; the DEA will continue to collaborate with state and local laboratories and make procedures available for verification and training.
